Antiviral PROTACs: Opportunity borne with challenge.

Liang, Jinsen; Wu, Yihe; Lan, Ke; Dong, Chune; Wu, Shuwen; Li, Shu; Zhou, Hai-Bing

Liang, Jinsen; Wu, Yihe; Lan, Ke; Dong, Chune; Wu, Shuwen; Li, Shu; Zhou, Hai-Bing.

Afiliación

Liang J; Medical Research Institute, Frontier Science Center for Immunology and Metabolism, Wuhan University, Wuhan, 430071, China.
Wu Y; Provincial Key Laboratory of Developmentally Originated Disease, Key Laboratory of Combinatorial Biosynthesis and Drug Discovery (MOE) and Hubei Province Engineering and Technology Research Center for Fluorinated Pharmaceuticals, School of Pharmaceutical Sciences, Wuhan University, Wuhan, 430071, Ch
Lan K; State Key Laboratory of Virology, College of Life Sciences, Wuhan University, Wuhan, 430072, China.
Dong C; Medical Research Institute, Frontier Science Center for Immunology and Metabolism, Wuhan University, Wuhan, 430071, China.
Wu S; State Key Laboratory of Virology, College of Life Sciences, Wuhan University, Wuhan, 430072, China.
Li S; Medical Research Institute, Frontier Science Center for Immunology and Metabolism, Wuhan University, Wuhan, 430071, China.
Zhou HB; Medical Research Institute, Frontier Science Center for Immunology and Metabolism, Wuhan University, Wuhan, 430071, China.

Cell Insight ; 2(3): 100092, 2023 Jun.

Article en En | MEDLINE | ID: mdl-37398636

Palabras clave

Antiviral drugs; Drug resistance; E3 ligase; PROTACs; Virus

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Idioma: En Revista: Cell Insight Año: 2023 Tipo del documento: Article País de afiliación: China